Chongqing Zein Pharmaceutical Co., Ltd.

Founded in 2001, Chongqing Zein Pharmaceutical Co., Ltd. is a national high-tech enterprise integrating pharmaceutical R & D, production, sales, and health services. With a focus on the construction of a full-life cycle management service system for drugs, the company has established a biopharmaceutical preparation industry cluster in the manner of “platform + investment”. It takes MAH (Marketing Authorization Holder) as the core to provide the full-life-cycle services, including CDMO, trade promotion, and post-marketing research of drugs.

Zein Pharmaceutical isperforming the R & D on improved new drugs and Category I new drugs. It also cooperates with colleges and universities to carry out the research on cutting-edge drugs and has established a well-developed platform for the transformation of industry-university-research achievements. In recent years, the company has been granted 32 domestic invention patents and 8 international patents (including 2 in the United States, 2 in Europe, 1 in Japan, 2 in South Korea, and 1 in India). In this way, it has made planning for intellectual property rights for the products and built the patent barriers to provide comprehensive protection on its technologies.

The main direction of Zein’s products is high-end chemical generic drugs of nerve, endocrine, and cardio-cerebrovascular. Currently, the company has the production capacity of over 40 tons in active pharmaceutical ingredient (API), and its preparations include capsules, granules, tablets, suppositories, and other dosage forms. The company has a number of domestically first generic drugs and exclusive products. With the company’s own marketing network, which radiates more than 20 countries and covers major large and medium-sized cities in China, its orlistat API has dominated the world’s largest market share, Saige’en (tropisetron hydrochloride injection) once occupied more than 50% sales share of similar products in the Chinese market, and the domestically exclusive suplatast tosilate and ropinirole also present a good performance in the market. As Zein’s main varieties have been included in the national and local drug reimbursement lists, their subsequent sales will rise rapidly. The main products produced and sold by the company include orlistat API, orlistat capsules (Youngsure and Ali), tropisetron hydrochloride injection (Saige’en), suplatast tosilate granules, ropinirole hydrochloride tablets, and donepezil hydrochloride tablets.

Zein was awarded the “Hi-tech Enterprise”, “Key High-tech Enterprise of National Torch Program”, “Chongqing Intellectual Property Advantage Enterprise”, and “Small and Medium-sized Enterprise Informatization Construction Model”. “Youngsure”, one of the company’s trademark, was granted as the “Famous Trademark of Chongqing” and “Famous Trademark of Hi-tech Zone” in 2013. The company has formed an R & D system with its own characteristics and core technologies in the aspects of full synthesis and structural transformation of natural active products as well as directional catalysis and quality control of chiral drugs, and has been approved to establish the Chongqing Chiral Drugs Engineering Technology Research Center, Chongqing New Drug Design Engineering Technology Research Center, a postdoctoral workstation, and Drug Advanced Manufacturing Technology National and Local Joint Engineering Research Center (a national-level engineering technology research center). From January to July 2020, it achieved an output value of RMB 1.16 billion, which is an 84.1% year-on-year growth.